Price T Rowe Associates Inc Larimar Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 13,460 shares of LRMR stock, worth $113,602. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,460Holding current value
$113,602% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
115Shares Held
67.7MCall Options Held
290KPut Options Held
38.9K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$179 Million3.23% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$51 Million0.66% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$36.9 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.33MShares$36.6 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.86MShares$32.6 Million11.62% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $365M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...